Immune Modulation – Ayurved Healing

Panchakarma for Autoimmune Conditions: Evidence Review and Clinical Considerations

Dr. Meera Iyer — Sun, 28 Jun 2026 10:30:00 +0000

Panchakarma’s role in autoimmune disease is best described with precision and caution. In Ayurveda, Panchakarma is a physician-directed Shodhana approach used after preparation to mobilize and eliminate vitiated Doshas; in autoimmune care, the most defensible role is adjunctive support, not replacement of disease-modifying medical treatment. The published human literature is most developed around Amavata-like presentations of rheumatoid arthritis and plaque psoriasis, while lupus, Hashimoto’s thyroiditis, multiple sclerosis, and other autoimmune conditions require a more conservative, case-by-case approach.

This review keeps the focus on what can be responsibly said: how Panchakarma is defined, where Ayurvedic reasoning is strongest, which modern clinical and mechanistic findings are relevant, and what safety boundaries should guide real-world autoimmune care.

What Panchakarma Actually Is: A Brief Clarification for Non-Specialists

Panchakarma literally means “five actions” or “five procedures.” In current Ayurvedic teaching and public-health descriptions, it is commonly presented as Vamana, Virechana, Basti, Nasya, and Raktamokshana. Some classical and teaching traditions enumerate the five by counting Niruha Basti and Anuvasana Basti separately instead of listing Raktamokshana. This difference in enumeration matters because modern articles, clinics, and studies may use “Panchakarma” to mean a complete staged regimen, a shortened residential program, or one selected procedure.

Vamana: Therapeutic emesis, traditionally used when Kapha is dominant and the patient is suitable for such a procedure.
Virechana: Therapeutic purgation, commonly used for Pitta-predominant disorders and conditions involving bowel-mediated elimination.
Basti: Medicated enema therapy, especially central in Vata disorders and systemic Dosha management.
Nasya: Administration of medicated substances through the nasal route, especially for conditions of the head, neck, senses, and upper channels.
Raktamokshana: Bloodletting therapy, classically described for selected Rakta and Pitta disorders, but used selectively and with major restrictions in modern practice.

Panchakarma is not meant to begin abruptly. It is traditionally preceded by Snehana (internal and external oleation) and Svedana (sudation or therapeutic sweating), and followed by a graduated post-procedure diet and recovery routine. For autoimmune patients, this staging is especially important because appetite, bowel function, sleep, hydration, medication timing, disease activity, and physical strength all affect suitability.

Why Autoimmune Conditions Require a Conservative Integrative Frame

Autoimmune disorders involve immune-mediated tissue injury, relapsing-remitting patterns, and, in many conditions, risk of irreversible organ damage. Panchakarma can affect digestion, bowel habits, fluid balance, rest, stress load, and medication routines; therefore, stable disease is very different from an active flare. A person with active fever, infection, dehydration, severe anemia, pregnancy, organ-threatening autoimmune disease, acute nephritis, neurological worsening, uncontrolled thyroid status, or marked frailty is not an appropriate candidate for intensive purification procedures without specialist clearance.

The safest clinical frame is integrative: Panchakarma may be considered only when the patient’s conventional diagnosis is clear, disease activity is assessed, current medications are known, baseline laboratory markers are available, and both the Ayurvedic physician and the relevant medical specialist agree on monitoring. The goal is supportive improvement in symptoms, digestion, metabolic resilience, function, and quality of life—not unsupervised withdrawal of corticosteroids, DMARDs, biologics, thyroid hormone, or disease-modifying neurological therapy.

Rheumatoid Arthritis (Amavata): The Most Developed Clinical Area

Rheumatoid arthritis is often discussed in Ayurveda through the clinical lens of Amavata. Classical descriptions of Amavata emphasize the association of Ama with aggravated Vata, producing pain, stiffness, heaviness, swelling, and joint involvement. This is not a one-to-one replacement for the modern diagnosis of rheumatoid arthritis, but it is a useful Ayurvedic clinical framework for inflammatory, painful, stiff, function-limiting joint disease.

Published human work in rheumatoid arthritis includes a 36-week double-blind randomized pilot trial comparing classical Ayurvedic treatment, methotrexate, and their combination in seropositive rheumatoid arthritis. The trial was small, but it is important because it treated Ayurveda as a whole-system intervention and used modern RA outcomes such as DAS28-CRP, ACR response criteria, and HAQ-DI. A later whole-system Ayurveda study in rheumatoid arthritis also described clinical improvement alongside movement of serum metabolic markers toward a healthier profile. These findings support careful integrative investigation, but they do not justify replacing standard RA disease-modifying therapy.

In Ayurvedic planning for Amavata, intensive procedures are usually not the first step. The sequence commonly begins with Deepana-Pachana measures to kindle digestion and reduce Ama, along with suitable diet, rest, and local or systemic procedures chosen according to strength and disease stage. Virechana and Basti may be selected in appropriate patients, but their timing should be individualized; heavy oleation or intensive purification during an unsuitable stage can aggravate symptoms.

Psoriasis and Psoriatic Disease: Stronger Procedural Literature Than Many Autoimmune Conditions

Plaque psoriasis is commonly approached in Ayurveda under Kushtha or Eka-Kushtha-type frameworks, with attention to Kapha, Vata, Pitta, Rakta, skin channels, digestion, and recurrence tendency. Among autoimmune and immune-mediated conditions, psoriasis has more direct procedural Ayurvedic literature than many others.

An open-label multicentric prospective study in plaque psoriasis used a comprehensive Ayurvedic protocol that included Vamana Karma, Takradhara, and Rasayana therapy over a structured treatment period. The study reported improvement in PASI and dermatology quality-of-life scores, with routine liver and kidney safety parameters remaining within acceptable limits in the reported cohort. Because this was open-label rather than blinded and placebo-controlled, the result is best interpreted as supportive clinical evidence for supervised adjunctive care, not as proof of universal efficacy.

Psoriatic arthritis requires additional caution because it can damage joints and may require rheumatology-directed DMARDs or biologics. Panchakarma may be considered only as an adjunct in stable patients, with dermatology and rheumatology coordination and clear agreement that prescribed systemic medicines are not to be stopped without specialist instruction.

Lupus (SLE): Case-Level Ayurvedic Literature and High Safety Requirements

Systemic lupus erythematosus is a multi-system autoimmune disease that can affect skin, joints, blood, kidneys, nervous system, and other organs. Ayurveda does not reduce all lupus presentations to one single classical label; depending on the dominant features, clinicians may reason through frameworks such as Vatarakta, Rakta Dushti, Kushtha-like skin involvement, inflammatory Pitta-Rakta patterns, and multi-channel disturbance.

Published Ayurvedic material for SLE includes case-report level work, including an SLE overlap vasculitis case managed with oral Ayurvedic medicines, suitable Panchakarma procedures, and wound care. This type of literature can inform individualized clinical reasoning, but lupus remains a high-risk condition for intensive Shodhana because disease flares may be unpredictable and organ-threatening.

For SLE, Panchakarma should be considered only in documented stable disease or remission, and only after rheumatology clearance. Active flare, lupus nephritis, central nervous system lupus, serious cytopenias, fever, infection, pregnancy, high-dose steroid instability, or recent hospitalization should lead to deferral of intensive purification. Hydroxychloroquine, corticosteroids, and immunosuppressive medicines should never be stopped abruptly for Panchakarma.

Hashimoto’s Thyroiditis: Adjunctive Metabolic and Symptom Support

Hashimoto’s thyroiditis is an autoimmune thyroid disorder in which immune mechanisms target thyroid tissue and may lead to hypothyroidism. Ayurveda does not name Hashimoto’s as a classical disease category, so the condition should not be forced into a single ancient diagnosis. Visible neck swelling or goitre-like presentations may be discussed through Galaganda, which is classically associated with swelling in the neck region and often interpreted through Kapha-Vata and tissue-channel involvement; however, many Hashimoto’s patients have no visible goitre and require individualized assessment.

The Ayurvedic focus in Hashimoto’s-type presentations is usually on digestion, Kapha-Vata balance, bowel function, weight change, fatigue, cold intolerance, sleep, menstrual status, stress, and associated inflammatory or metabolic features. Published Ayurvedic literature is mainly case-report level, including reports using approaches such as Virechana, Shiro Takradhara, Abhyanga, and internal Shamana medicines. These reports are useful as clinical signals, not as a basis for stopping thyroid hormone.

Patients taking levothyroxine should continue it unless an endocrinologist changes the dose. Thyroid monitoring should include TSH and, when clinically appropriate, free T4; dose-related reassessment is commonly done after several weeks because levothyroxine adjustment requires time to reach a steady state. Panchakarma scheduling should be planned so that medicine timing, fasting, purgation, and post-procedure diet do not interfere with thyroid replacement consistency.

Mechanisms That Are Plausible but Should Not Be Overstated

The most sensible mechanistic explanation is systems-level rather than single-target. Panchakarma combines dietary control, digestive preparation, oleation, sweating, elimination procedures, rest, reduced sensory load, and post-procedure rebuilding. Each of these can influence digestion, bowel function, sleep, stress physiology, metabolism, and inflammatory tone in ways that may matter for autoimmune patients.

Published human data describe metabolomic changes after a Panchakarma-based intervention in healthy adults, including shifts in lipid-related metabolic pathways. A small human detoxification study reported reductions in measured lipid-soluble environmental contaminants after an Ayurvedic detoxification procedure. Modern gut-immune literature also links dysbiosis and intestinal immune signaling with rheumatoid arthritis and other immune-mediated diseases. These findings make the biological rationale for supervised Ayurvedic protocols plausible, while condition-specific outcomes still depend on diagnosis, disease activity, patient strength, medicines, diet, and monitoring.

Clinical Suitability and Monitoring

The following table summarizes a conservative clinical approach. It is not a self-treatment guide; it is a framework for discussion between the patient, Ayurvedic physician, and relevant specialist.

Condition	Panchakarma Suitability	Key Cautions	Coordination Required
Rheumatoid arthritis / Amavata-like stable inflammatory arthritis	Potential adjunct when disease is stable and patient strength is adequate	Continue DMARDs unless rheumatologist changes them; monitor pain, stiffness, function, CRP/ESR, liver and kidney safety markers when relevant	Rheumatologist + qualified Ayurvedic physician
Lupus / SLE	Highly selective; stable remission only	Avoid during flare, nephritis, CNS lupus, cytopenia, infection, pregnancy, or steroid instability; never abruptly stop steroids or immunosuppressants	Rheumatologist clearance is mandatory
Hashimoto’s thyroiditis	Adjunctive support for digestion, metabolism, symptoms, and constitutional imbalance	Continue levothyroxine unless endocrinologist adjusts dose; monitor TSH/free T4; avoid disrupting medicine timing	Endocrinologist + qualified Ayurvedic physician
Plaque psoriasis	Reasonable adjunct in selected stable patients, with more direct procedural Ayurvedic literature than many autoimmune conditions	Assess severity, skin infection risk, hydration, and medication interactions; do not self-stop systemic steroids, methotrexate, cyclosporine, or biologics	Dermatologist + qualified Ayurvedic physician
Psoriatic arthritis	Adjunct only; joint-protective medical treatment remains central	Monitor joint swelling, morning stiffness, function, and inflammatory markers; do not interrupt DMARDs or biologics without rheumatology direction	Rheumatologist + dermatologist + Ayurvedic physician
Multiple sclerosis	Not established as disease-modifying care; supportive use only if neurologist agrees	Do not interrupt disease-modifying therapy; avoid procedures during relapse, infection, severe fatigue, dehydration, or neurological instability	Neurologist mandatory

Practical Bottom Line

Panchakarma may have a place in autoimmune care when it is individualized, medically coordinated, and used as an adjunct in stable patients. The strongest Ayurvedic rationale and human literature are in Amavata-like rheumatoid arthritis care and plaque psoriasis protocols; lupus, Hashimoto’s thyroiditis, multiple sclerosis, and other autoimmune conditions require stricter selection and monitoring. The safest goal is not “detox as cure,” but a supervised attempt to improve digestion, functional capacity, symptom burden, metabolic resilience, and quality of life while preserving essential disease-modifying medical care.

For related content on Panchakarma preparation and beginners’ guidance, see our article on Panchakarma preparation for beginners. For the specific Amavata approach, see our article on Amavata protocol and Ayurvedic RA care.

Disclaimer: This article is for educational and informational purposes only. Panchakarma for autoimmune conditions should be pursued only under the supervision of a qualified Ayurvedic physician and the patient’s rheumatologist, endocrinologist, dermatologist, neurologist, or relevant healthcare provider. Never discontinue corticosteroids, DMARDs, biologic agents, thyroid hormone, hydroxychloroquine, immunosuppressants, or disease-modifying neurological therapy without specialist guidance. This article does not diagnose, treat, or replace medical care.

References

Interleukin Modulation by Ayurvedic Herbs: Anti-Cytokine Storm Evidence

Dr. Meera Iyer — Mon, 18 May 2026 09:00:00 +0000

The term “cytokine storm” entered mainstream medical vocabulary during the COVID-19 pandemic, although immunologists had studied the phenomenon in influenza, sepsis, and autoimmune disease for decades. The hyperinflammatory immune response that characterises severe viral illness — in which IL-6, TNF-alpha, IL-1beta, and IFN-gamma escalate in a self-reinforcing cascade — became a focus of both new drug development and renewed interest in established anti-inflammatory agents. Laboratory and early clinical studies suggest that several plants used in Ayurveda interact with specific interleukin and cytokine pathways, though it must be stated plainly that most of this evidence remains preclinical and mechanistic rather than confirmatory.

This is not a claim that Ayurveda treats COVID-19 or any specific infectious disease. It is a pharmacological and classical review of documented mechanisms and traditional usage, presented with their appropriate clinical limits.

The Cytokine Storm: Mechanism and Targets

Under normal immune activation, dendritic cells and macrophages release cytokines that coordinate a measured inflammatory response. In cytokine storm this regulation fails: positive-feedback loops among IL-6, TNF-alpha, and IL-1beta create a self-amplifying cascade that injures healthy tissue, particularly the lung endothelium and vascular system. The principal therapeutic targets identified in the immunological literature include:

IL-6: the primary driver of the acute-phase response; its receptor is the target of the monoclonal antibody tocilizumab used in severe COVID-19
TNF-alpha: central to the NF-kB inflammatory pathway; elevated in sepsis, autoimmune conditions, and severe infection
IL-1beta: activates the NLRP3 inflammasome, triggering pyroptosis and vascular leakage
IFN-gamma: drives the macrophage activation syndrome associated with haemophagocytic lymphohistiocytosis
NLRP3 inflammasome: the molecular platform on which IL-1beta maturation depends; an emerging drug target across multiple inflammatory conditions

Guduchi (Tinospora cordifolia): The Most Studied Ayurvedic Immunomodulator

Guduchi (giloy, Tinospora cordifolia) is among the most extensively investigated herbs of the Ayurvedic materia medica. Classical texts give it the name Amrita, “the nectar of immortality,” and Charaka places it among the Vayasthapana (age-sustaining), Trishna-nigrahana (thirst-relieving), and Dahaprashamana (heat-quelling) groups of herbs. Its rasa (taste) is tikta (bitter) and kashaya (astringent), its virya (potency) ushna (heating), and its vipaka (post-digestive effect) madhura (sweet); it is classically regarded as tridoshahara and as a premier Rasayana (rejuvenative) used to rebuild strength and resilience after illness.

Phytochemically, Tinospora contains several chemically distinct classes of constituent, which should not be conflated: isoquinoline-type alkaloids such as berberine, palmatine, and magnoflorine; diterpenoid furanolactones such as columbin and tinosporide; clerodane glycosides such as tinocordiside and cordifolioside; and an immunologically active arabinogalactan polysaccharide. Columbin is a bitter diterpenoid lactone, not an alkaloid, and berberine is a separate isoquinoline alkaloid — the two belong to different chemical families and are not interchangeable names for one compound. Experimental reviews of the plant attribute much of its immunomodulatory activity to the arabinogalactan polysaccharide and report that the herb acts bidirectionally rather than as a simple immunosuppressant: in immunodeficient models it enhances natural-killer-cell activity and macrophage phagocytosis, while in hyperinflammatory models it dampens pro-inflammatory cytokine output. This normalising, bidirectional character is consistent with the classical understanding of Guduchi as a Rasayana rather than a single-target drug.

In classical practice Guduchi is rarely given as a crude alkaloid. It is used as Guduchi Satva (the starch-like aqueous extract), as Samshamani Vati (also called Guduchi Ghana Vati, the solidified decoction), and within compound formulations such as Amritarishta and Guduchyadi Kashaya, classically indicated in Jvara (fever) — particularly Jirna Jvara, the chronic or lingering fever — as well as in Vatarakta and Prameha. These traditional indications align with the herb’s documented anti-inflammatory and immunomodulatory pharmacology, but rigorous human trials specific to cytokine-storm conditions are still lacking, and that gap should not be overstated.

Yashtimadhu (Glycyrrhiza glabra): Glycyrrhizin and HMGB1

Yashtimadhu (licorice root, Glycyrrhiza glabra; also Madhuyashti or Mulethi) is one of the most valued herbs of classical Ayurveda, included in Charaka’s Jivaniya (life-promoting), Kanthya (voice-improving), Varnya (complexion-improving), and Sandhaniya groups. Its rasa is madhura (sweet), its virya sheeta (cooling), and its vipaka madhura, and it is traditionally used as a Rasayana for the respiratory tract and throat. Its principal triterpenoid saponin, glycyrrhizin, has a well-characterised anti-inflammatory profile:

It binds directly to HMGB1 (high-mobility group box 1 protein) and inhibits its cytokine activity — HMGB1 being a late-phase mediator that sustains inflammation after the initial infectious trigger has been controlled
It is reported to reduce NLRP3 inflammasome activation, limiting IL-1beta maturation
It modulates interferon and JAK-STAT signalling in experimental systems
It inhibits phospholipase A2, reducing arachidonic-acid release and downstream prostaglandin and leukotriene production

Herb	Sanskrit Name	Primary Cytokine Target	Mechanism	Study Evidence Level
Tinospora cordifolia	Guduchi	IL-6, TNF-alpha	NF-kB suppression, macrophage modulation	Preliminary (in vitro and animal)
Glycyrrhiza glabra	Yashtimadhu	IL-1beta, IFN-gamma, HMGB1	NLRP3 inhibition, JAK-STAT suppression	High in vitro, moderate in vivo
Curcuma longa	Haridra	TNF-alpha, IL-1beta, IL-6	NF-kB inhibition, COX-2 suppression	High (multiple human RCTs)
Withania somnifera	Ashwagandha	IL-6, TNF-alpha	Withanolide A NF-kB inhibition	Moderate (human and animal)
Andrographis paniculata	Kalamegha / Bhunimba	IL-6, IL-12, IFN-gamma	Andrographolide NF-kB and STAT3 modulation	Moderate (human trials in respiratory infection)
Phyllanthus niruri	Bhumyamalaki	TNF-alpha, IL-10 (immunomodulatory)	Lignans inhibit viral replication and macrophage activation	Moderate (mostly in vitro)

Andrographis paniculata (Bhunimba / Kalamegha): The NF-kB and STAT3 Modulator

In Ayurveda Andrographis paniculata is known by the Sanskrit names Bhunimba (“neem of the ground,” for its intense bitterness) and Kalamegha; “Kalmegh” is the common Hindi and Bengali vernacular form rather than the classical Sanskrit or pharmacopoeial name. It is an intensely tikta (bitter) herb used classically as a deepana-pachana (digestion-kindling) agent and as a remedy for fever and liver disorders, especially in Pittaja jvara and in afflictions of the Yakrit (liver). Its primary diterpene lactone, andrographolide, has been studied as an inhibitor of the two transcription factors most central to cytokine-storm amplification, NF-kB and STAT3:

It forms a covalent adduct with reduced cysteine 62 of the NF-kB p50 subunit, blocking the protein’s binding to DNA and thereby suppressing NF-kB-driven transcription
It is reported to interfere with STAT3 activation, the pathway through which IL-6 propagates its inflammatory signal
In cell-culture models it reduces replication of several respiratory viruses, an effect attributed in part to interference with viral protease activity

Andrographis has been evaluated in human trials for uncomplicated upper-respiratory-tract infection, where it has shown modest symptomatic benefit. Claims of dramatic benefit in COVID-19, however, are not supported by reliable randomised evidence; existing trials of standardised andrographolide doses have not demonstrated a consistent, clinically meaningful advantage, and the herb should not be presented as a proven antiviral therapy.

The Classical Formula Approach: Sudarshana Churna

Classical Ayurveda rarely treats Jvara (fever) with a single herb. Instead it relies on compound formulas (yoga) in which many bitter, deepana-pachana herbs are combined to digest Ama (undigested metabolic residue) and rebalance the doshas. Sudarshana Churna (in its larger form Mahasudarshana Churna), described in classical compendia such as the Bhaishajya Ratnavali, is among the most widely used Ayurvedic antipyretic formulas. Built around the intensely bitter Kiratatikta (Swertia chirata) together with Guduchi and a large number of supporting herbs, it is classically indicated in Vishama Jvara — the irregular, recurrent, and intermittent fevers that include malaria-like and chronic febrile patterns.

A related and frequently cited Tamil formula, Nilavembu Kudineer, is used for similar febrile and inflammatory conditions, but it belongs to the Siddha system — a distinct classical tradition of South India — and does not appear in the Ayurvedic classical texts or the Ayurvedic Pharmacopoeia of India; it should therefore not be described as an Ayurvedic formula. Within Ayurveda itself, the rationale for multi-herb antipyretics is the principle of synergy: bitter herbs such as Kiratatikta and Guduchi supply the central febrifuge and Ama-digesting action; aromatic and pungent additions such as dry ginger (Shunthi) and the Trikatu group act as deepana and as anupana that aid absorption; and the whole is held to function as a balanced pharmacological ensemble rather than as a single isolated molecule.

Safety Considerations for Cytokine-Modulating Herbs

Enthusiasm for cytokine-modulating herbs must be matched by explicit safety awareness, because several of these plants carry genuine risks at therapeutic doses:

Yashtimadhu: glycyrrhizin raises blood pressure through mineralocorticoid-like activity and can cause hypokalaemia and fluid retention. It is contraindicated in uncontrolled hypertension and should not be taken at high doses for more than four to six weeks without medical supervision.
Andrographis: animal studies suggest it may reduce sperm parameters at high doses, so it is best avoided by men actively trying to conceive; it may also potentiate anticoagulant and antiplatelet medicines.
Guduchi: published case series have linked some commercial Tinospora cordifolia preparations to herb-induced liver injury, including an autoimmune-pattern hepatitis. Correct botanical identification and quality-verified sources are essential, and unexplained jaundice warrants stopping the herb and seeking medical care.
Curcumin (Haridra): can inhibit platelet aggregation, warranting caution with anticoagulants, and inhibits CYP3A4, potentially altering the levels of many prescription medicines.

For anyone receiving immunosuppressive therapy for autoimmune disease or organ transplantation, cytokine-modulating herbs require careful medical supervision, because their effects on immune regulation may interact unpredictably with pharmaceutical immunosuppressants.

The immunological themes here connect to the broader Ayurvedic anti-inflammatory framework covered in the Ayurvedic anti-inflammatory diet. For further pharmacological context, the herb-drug interactions safety guide provides essential reference for herb-medication combinations.

This is a pharmacological and classical review for educational purposes only. None of the herbs or formulas described here should be used as a first-line treatment for COVID-19, sepsis, or any acute inflammatory condition requiring urgent medical care. Always consult a qualified healthcare provider and a registered Ayurvedic practitioner before using cytokine-modulating herbs, particularly if you take immunosuppressants, anticoagulants, or antiviral medicines.